Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Author:
Affiliation:
1. Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan
2. PMS Center, Real World Evidence Business Headquarters, EPS Corporation, Tokyo, Japan
Funder
Boehringer Ingelheim Co., Ltd. and Eli Lilly Japan K.K
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1859477
Reference34 articles.
1. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
2. null
3. Ministry of Health Labour and Welfare. Patient Survey 2017 [cited 2020 Mar 30]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/dl/toukei.pdf (Japanese).
4. Diabetes in Older Adults
5. Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study;Expert Opinion on Drug Safety;2022-08-16
2. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections;Expert Opinion on Drug Safety;2022-02-25
3. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials;Expert Opinion on Drug Safety;2021-11-10
4. Multiple drugs;Reactions Weekly;2021-07
5. Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study;Diabetes, Obesity and Metabolism;2021-02-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3